Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907735 · ClinicalTrials.gov registry record
Oxytocin Receptor Expression in Pregnancy
A clinical trial of Post-Abortion and Hemorrhage, Obstetric, sponsored by Oregon Health and Science University.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT03907735: Active study of Post-Abortion and Hemorrhage, Obstetric, sponsored by Oregon Health and Science University.
NCT03907735 is a study of Post-Abortion and Hemorrhage, Obstetric that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03907735, a study of Post-Abortion and Hemorrhage, Obstetric, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine when during gestation oxytocin receptor (OXTR) expression increases in the myometrium, which will contribute new insight to the management of obstetric hemorrhage and our understanding of normal and abnormal labor.
Primary Outcome
Measure of oxytocin receptor expression. Perform quantitative RT-PCR on mRNA extracted from biopsy samples obtained from subjects at the end of their procedure (within 30 minutes).
Conditions Studied
Interventions
- OTHER Myometrial tissue sample collection
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2025-08 |
What the registry record for NCT03907735 still lists
NCT03907735 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 2 conditions, with Post-Abortion appearing as the primary indexed condition, and to 1 intervention - of which Myometrial tissue sample collection is the first listed.
NCT03907735 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03907735 about?
NCT03907735 is a clinical study titled "Oxytocin Receptor Expression in Pregnancy". This study aims to determine when during gestation oxytocin receptor (OXTR) expression increases in the myometrium, which will contribute new insight to the management of obstetric hemorrhage and our understanding of normal and abnormal labor.
What is the current status of trial NCT03907735?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2019-06-03. Estimated completion is 2025-08.
What conditions does trial NCT03907735 study?
This clinical trial studies the following conditions: Post-Abortion, Hemorrhage, Obstetric.
What interventions are being tested in trial NCT03907735?
The interventions under investigation include: Myometrial tissue sample collection (OTHER).
Who is sponsoring clinical trial NCT03907735?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03907735 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI